Regeneron Pharmaceuticals (REGN) Goodwill & Intangibles (2021 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Goodwill & Intangibles of $1.3 billion for Q2 2026, up 745.03% year-over-year from $155.0 million in Q2 2025, and up 1.78% quarter-over-quarter from $1.3 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Goodwill & Intangibles (2021 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Goodwill & Intangibles history runs 6 years deep, the most recent figure standing at $1.3 billion for Q2 2026.
- In Q2 2026, Goodwill & Intangibles rose 745.03% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (up 745.03% YoY), while the FY2025 annual figure was $1.3 billion, up 9.47% from the prior year.
- Goodwill & Intangibles for Q2 2026 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $1.4 billion in Q3 2025, with the low at $155.0 million in Q2 2025.
- The 5-year median for Goodwill & Intangibles is $1.1 billion (2024), against an average of $1.0 billion.
- The sharpest annual moves came in 2022 and 2025: Goodwill & Intangibles soared 13564.18% in 2022, then sank 85.94% in 2025.
- Regeneron Pharmaceuticals' Goodwill & Intangibles stood at $915.5 million in 2022, then increased by 13.45% to $1.0 billion in 2023, then grew by 10.59% to $1.1 billion in 2024, then advanced by 9.47% to $1.3 billion in 2025, then rose by 4.17% to $1.3 billion in 2026.
- Business Quant data shows REGN's Goodwill & Intangibles at $1.3 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.29 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 155.00 Mn |
| Mar 31, 2025 | 1.17 Bn |
| Dec 31, 2024 | 1.15 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 1.06 Bn |
| Dec 31, 2023 | 1.04 Bn |
| Sep 30, 2023 | 1.02 Bn |
| Jun 30, 2023 | 953.00 Mn |
| Mar 31, 2023 | 928.70 Mn |
| Dec 31, 2022 | 915.50 Mn |
| Sep 30, 2022 | 956.30 Mn |
| Dec 31, 2021 | 6.70 Mn |